Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643043 · ClinicalTrials.gov registry record · NA
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
A NA study of Bladder Cancer and Urothelial Carcinoma, sponsored by Matthew Milowsky, MD.
- Completed
- Registry status
- NA
- Development phase
- 219
- Enrollment target
- 8
- Study locations
NCT02643043 is a NA study of Bladder Cancer and Urothelial Carcinoma that has completed, run by Matthew Milowsky, MD. The registered enrollment target is 219 participants, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT02643043, a NA study of Bladder Cancer and Urothelial Carcinoma, has completed, sponsored by Matthew Milowsky, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 219 participants
- Enrollment target
- 8
- Study locations
Study Summary
This comprehensive genomic analysis and biospecimen repository study incorporates Next Generation Sequencing (NGS) of archival tumor tissue from 200 subjects with metastatic urothelial cancer in support of several parallel goals. The immediate goal involves generation of a comprehensive report identifying subject specific genetic mutations and/or alterations based on NGS. Additionally, DNA and RNA extracted from tumor specimens and any remaining blocks/slides from the NGS will be stored for future research. Long-term, the goal of this endeavor is to support collaborative translational research projects in metastatic urothelial cancer by allowing investigators to interrogate abstracted coded clinical data linked to data from any biospecimen studies.
Conditions Studied
Interventions
- OTHER Biospecimen Collection
Study Locations (8)
New York
- Ichan School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- University of Southern Cailfornia - Los Angeles
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
North Carolina
- University of North Carolina - Lineberger Comprehensive Cancer Center - Chapel Hill
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Washington
- University of Washignton/Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2023-09-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643043
The ClinicalTrials.gov registry entry for NCT02643043 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Matthew Milowsky, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT02643043 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02643043 about?
NCT02643043 is a clinical study titled "UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch". This comprehensive genomic analysis and biospecimen repository study incorporates Next Generation Sequencing (NGS) of archival tumor tissue from 200 subjects with metastatic urothelial cancer in support of several parallel goals. The immediate goal involves generation of a comprehensive report ident...
What is the current status of trial NCT02643043?
This trial is currently completed. It is a NA study. The enrollment target is 219 participants. The study started on 2017-07-26. Estimated completion is 2023-09-13.
What conditions does trial NCT02643043 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Urethral Cancer, Cancer of the Ureter.
What interventions are being tested in trial NCT02643043?
The interventions under investigation include: Biospecimen Collection (OTHER).
Who is sponsoring clinical trial NCT02643043?
This trial is sponsored by Matthew Milowsky, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02643043 being conducted?
This trial has 8 study locations across California, Illinois, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.